Dupilumab for the treatment of alopecia areata in children with atopic dermatitis

Abstract

Alopecia Areata (AA) often co-occurs with atopic dermatitis (AD), with up to one-third of patients with AA also affected by AD.1,2 Dupilumab, an interleukin 4 receptor antagonist, Food and Drug Administration-approved for the treatment of moderate-to-severe AD in patients 6 years and older, has begun to receive some interest for a potential role in the treatment of AA. While some case reports and series have demonstrated improvement of AA with dupilumab,3-6 there are also reports of patients developing new-onset hair loss during treatment.

Topics & Concepts